Karyopharm reports fourth quarter and full year 2024 financial results, announces update to phase 3 xport-ec-042 trial and highlights recent company progress

– total revenue of $145 million and u.s. xpovio® (selinexor) net product revenue of $113 million for full year 2024 – – top-line data readout from phase 3 sentry trial evaluating selinexor in combination with ruxolitinib in patients with jaki-naÏve myelofibrosis anticipated in 2h 2025; company on track to complete enrollment in 1h 2025 – – company announces update to phase 3 xport-ec-042 trial of selinexor as maintenance therapy in advanced or recurrent tp53 wild-type endometrial cancer. following dialogue with the fda regarding the evolving treatment landscape, trial to focus enrollment on patients with either pmmr tumors or patients with dmmr tumors that are medically ineligible for checkpoint inhibitors.
KPTI Ratings Summary
KPTI Quant Ranking